Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $2.00 target price on shares of Aptose Biosciences in a research note on Friday, January 10th.

Aptose Biosciences Stock Up 0.4 %

Shares of NASDAQ APTO opened at $0.21 on Thursday. Aptose Biosciences has a 52-week low of $0.13 and a 52-week high of $2.30. The business’s 50 day moving average is $0.24 and its two-hundred day moving average is $0.39. The firm has a market cap of $12.46 million, a price-to-earnings ratio of -0.07 and a beta of 0.87.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent quarter. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.